PuSH - Publikationsserver des Helmholtz Zentrums München

Moser, R.* ; Pfeiffer, S.* ; Cala, L.* ; Klein, E.* ; Kiechle, M.* ; Behzadi, S.T.* ; Fallenberg, E.M.* ; Combs, S.E. ; Weber, W.* ; Borm, K.J.*

Detecting metastatic patterns of oligometastatic breast cancer: A comparative analysis of 18F-FDG PET/CT and conventional CT imaging.

J. Nucl. Med. 65, 845-850 (2024)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Metastasis-directed therapy has the potential to improve progression-free and overall survival in oligometastatic disease (OMD). For breast cancer, however, randomized trials have failed so far to confirm this finding. Because the concept of metastasis-directed therapy in OMD is highly dependent on the accuracy of the imaging modality, we aimed to assess the impact of 18F-FDG PET/CT on the definition of OMD in breast cancer patients. Methods: Eighty patients with a total of 150 18F-FDG PET/CT images (between October 2006 and January 2022) were enrolled in this retrospective study at the Technical University of Munich. The inclusion criteria were OMD, defined as 1-5 distant metastases, at the time of 18F-FDG PET/CT. For the current study, we systemically compared the metastatic pattern on 18F-FDG PET/CT with conventional CT. Results: At the time of 18F-FDG PET/CT, 21.3% of patients (n = 32) had a first-time diagnosis of metastatic disease, 40.7% (n = 61) had a previous history of OMD, and 38% (n = 57) had a previous history of polymetastatic disease. In 45.3% of cases, the imaging modality (18F-FDG PET/CT vs. conventional CT) had an impact on the assessment of whether OMD was present. An identical metastatic pattern was observed in only 32% of cases.18F-FDG PET/CT detected additional metastases in 33.3% of cases, mostly in the nonregional lymph node system. Conclusion: The use of 18F-FDG PET/CT had a substantial impact on the definition of OMD and detection of metastatic pattern in breast cancer. Our results emphasize the importance of establishing a standardized definition for imaging modalities in future trials and clinical practices related to metastasis-directed therapy in breast cancer patients.
Impact Factor
Scopus SNIP
Altmetric
9.100
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter 18f-fdg Pet/ct ; Omd ; Breast Cancer ; Oligometastatic Breast Cancer; F-18-fdg Pet/ct; Fdg-pet/ct; Radiation-therapy; Stage-iii; Radiotherapy; Oncology; Disease; Trial; Lung
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 0161-5505
e-ISSN 1535-5667
Quellenangaben Band: 65, Heft: 6, Seiten: 845-850 Artikelnummer: , Supplement: ,
Verlag Society of Nuclear Medicine and Molecular Imaging
Verlagsort 1850 Samuel Morse Dr, Reston, Va 20190-5316 Usa
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
PubMed ID 38637138
Erfassungsdatum 2024-06-05